Pharmaceutical Market Europe • November 2025 • 37
APPOINTMENTS
VALANX Biotech
Klaus Orlinger
VALANX Biotech has appointed Klaus Orlinger as Chief Scientific Officer. Orlinger brings previous expertise in the field of drug development programmes to his new role at VALANX, a company developing novel technology for site-specific protein conjugation in drug discovery. He previously spent more than 13 years at HOOKIPA Pharma, in roles including Head of Virology, Executive Vice President Research and, most recently, Chief Scientific Officer. He also worked as a scientist at Baxter. At VALANX, Orlinger will oversee the company’s drug development roadmap, including the progression of its GoldenSite conjugation platform and its application in discovering novel therapeutic protein conjugates.
Sanner
Stefan Verheyden
Sanner has appointed Stefan Verheyden as CEO. Over Verheyden’s more than three decades of experience in the pharma and biopharma industries, he held the roles of Global Vice President Pharma and Biopharma Injectables at Gerresheimer and Sr. Vice President Sales Pharmapackaging at Nipro Europe NV. He also held roles at Terumo and Avantor.
Enzymatica
Sana Alajmovic
Enzymatica has appointed Sana Alajmovic as CEO. From 2014, Alajmovic served as co-founder and CEO of Sigrid Therapeutics, where she drove strategic direction and promoted research and development. Other previous roles include Head of Business Development at Nanologica AB and Board Member roles at SwedenBIO and Berzelii Center EXSELENT.
Medidata
Lisa Moneymaker
Medidata has appointed Lisa Moneymaker as Chief Strategy Officer. Moneymaker has 25 years of experience in tech-enabled clinical development. She joined Medidata in 2024 as Senior Vice President of Strategic Customer Engagement. Other previous roles include Chief Strategy Officer, Chief Technology Officer and Chief Product Officer at Saama.
MedaSystems
Anton White
MedaSystems has appointed Anton White as Vice-President of Growth. White was previously Vice-President of Sales at Optum Life Sciences, where he delivered on annual sales and growth targets and collaborated across finance, legal, operations, product and marketing teams. He also held senior Sales Specialist roles at Lilly and Celgene.
ARTBIO
Robert Mittendorff
ARTBIO has appointed Robert Mittendorff to its board of directors. Mittendorff’s medicine and life sciences investment background includes serving as General Partner and Global Head of Healthcare at B Capital since 2021. Other roles include Board of Directors Member at Nalu Medical and Board Observer at Evommune and Nuvig Therapeutics.
ARTBIO
Gabe Gelman
ARTBIO has appointed Gabe Gelman to its board of directors. Gelman is currently Head of Capital Solutions at Baker Bros. Investments; his extensive portfolio of investment experience includes over 25 years in roles such as Managing Director, Partner and Head of Americas Equity Capital Markets at Goldman Sachs.
Atelerix
Catherine Elton
Atelerix has appointed Catherine Elton as Non-Executive Director. Elton’s more than 20 years of scientific and commercial leadership include a current role as Chief Business Officer at Axol Bioscience, as well as almost a decade as co-founder and CEO of Qkine. She also previously held multiple senior roles at Abcam.
Atelerix
Sunil Shah
Atelerix has appointed Sunil Shah as Chair of the Board. Shah brings extensive experience founding and investing in life sciences companies, serving as co-founder and CEO of o2h Ventures for over 22 years. Other roles include Board Member at Oxford Drug Design and the BioIndustry Association and Chairman of the Board at Exonate.